Two pioneering digital therapeutics (DTx) for addiction are available once again after their original developer Pear Therapeutics was dissolved last year. The two FDA-approved apps – RESET and RESET-O ...

Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients out of "at least ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...

All 15-year-old children in the UK should be offered the vaccine against meningitis B (MenB) in the wake of fatal outbreaks ...

For decades, pharmaceutical marketing has been built on a simple premise: if we present the right data, to the right audience ...

Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...

Andrew Witty had been CEO of UnitedHealth Group for four years. Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its financial forecasts ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...

Reports are emerging that a multibillion-dollar partnership between AbbVie and Alphabet-backed biotech Calico has come to an end after more than a decade. The divorce – first report by Stat – comes ...

Good Clinical Practice (GCP), the bedrock of ethical and high-quality clinical research, guides operations among sponsor companies, contract research organisations (CROs), investigator sites, and ...